Monte Rosa Therapeutics, Inc.
GLUE
$15.50
-$0.34-2.15%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 113.02% | 51.38% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 113.02% | 51.38% | |||
| Cost of Revenue | 9.96% | 4.84% | |||
| Gross Profit | 1.57% | -1.36% | |||
| SG&A Expenses | -2.51% | -1.46% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 7.10% | 3.33% | |||
| Operating Income | 1.81% | -0.64% | |||
| Income Before Tax | 2.84% | 3.53% | |||
| Income Tax Expenses | 300.00% | -11.86% | |||
| Earnings from Continuing Operations | 2.49% | 3.54% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 2.49% | 3.54% | |||
| EBIT | 1.81% | -0.64% | |||
| EBITDA | 1.64% | -0.79% | |||
| EPS Basic | 4.02% | 17.39% | |||
| Normalized Basic EPS | 4.35% | 17.38% | |||
| EPS Diluted | 4.44% | 16.56% | |||
| Normalized Diluted EPS | 4.35% | 17.38% | |||
| Average Basic Shares Outstanding | 1.60% | 16.76% | |||
| Average Diluted Shares Outstanding | 1.60% | 16.76% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||